画像誘導放射線治療市場 : 2028年までの世界予測

Report Overview

The global image-guided radiation therapy market is projected to reach USD 2.4 billion by 2028 from USD 1.9 billion in 2023, growing at a CAGR of 5.2% during the forecast period. The projected surge in market growth for image-guided radiation therapy (IGRT) is underpinned by a confluence of compelling advantages. Notably, IGRT’s capacity to achieve exceptional precision in tumor targeting, coupled with its ability to mitigate collateral damage to healthy tissues, stands as a pivotal driver. Furthermore, the escalating global incidence of cancer amplifies the demand for advanced treatment modalities, with IGRT positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of IGRT adoption in the forthcoming forecasting years.

“LINAC (linear accelerator) segment to register largest market share in 2022-2028.”
Based on the product, the image-guided radiation therapy market is segmented into 4D gating/ 4D RT, LINAC (linear accelerator), PET/ MRI-guided radiation therapy, CT scanning and portal imaging. LINAC (linear accelerator) segment to register the largest market share over the forecast period of 2022-2028. The realm of LINAC technology is marked by continuous evolution, characterized by progressive innovations encompassing imaging modalities, dose delivery methodologies, and treatment validation approaches. This evolutionary trajectory significantly contributes to the perpetual advancement of image-guided radiation therapy (IGRT), thereby playing a pivotal role in amplifying its market presence and prominence.

“The Prostate cancer application segment to register highest CAGR over the forecast period of 2023-2028.”
Based on the application, the image-guided radiation therapy market is segmented into prostate cancer, lung cancer, head & neck cancer, breast cancer, gastrointestinal cancer, gynecological cancer, and other applications. The rising worldwide prevalence of prostate cancer has catalyzed a discernible surge in the need for advanced and effective treatment methodologies. Within this framework, image-guided radiation therapy (IGRT) assumes a pivotal stance, proffering meticulous tumor targeting founded on precision and augmenting therapeutic outcomes. This escalating requirement for elevated treatment sophistication seamlessly converges with the inherent attributes of IGRT, thereby substantiating its central position in propelling market expansion within the sphere of prostate cancer radiation therapy.


“The Stereotactic therapy procedure segment accounted for the highest CAGR of the image-guided radiation therapy market over the forecasting period.”
Based on the procedure, the image-guided radiation therapy market is segmented into 3D conformal therapy, IMRT, stereotactic therapy, particle therapy and proton beam therapy. The stereotactic therapy procedure segment exhibited the most substantial Compound Annual Growth Rate (CAGR) within the image-guided radiation therapy market over the projected forecasting period.
Stereotactic therapy possesses distinct qualities, notably its abbreviated treatment duration and elevated precision, which notably elevate the comfort levels of patients undergoing radiation therapy. This enhancement in the holistic treatment experience aligns seamlessly with the patient-centric philosophy that underscores image-guided radiation therapy (IGRT). The convergence of these attributes not only cultivates positive patient outcomes but also amplifies IGRT’s appeal within the market landscape, consequently fostering heightened adoption rates and a more pronounced market presence.

“Hospitals’ segment to register for the largest market share of the image-guided radiation therapy market in 2022-2028.”
The major end users in the image-guided radiation therapy market are hospitals. The hospital end-user segment is estimated to hold a significant market share of the image-guided radiation therapy market during the forecast period. Hospitals, characterized by their capacity to provide a comprehensive array of medical services within a singular facility, confer a distinctive convenience to patients undergoing image-guided radiation therapy (IGRT). This convenience stems from the consolidation of diverse medical needs under one roof, thereby mitigating the necessity for patients to seek multiple appointments at disparate venues. This strategic amalgamation of services not only streamlines patient care but also augments the attractiveness of IGRT as a preferred treatment option. As a result, this seamless alignment of convenience and comprehensive care significantly contributes to the advancement and prominence of the image-guided radiation therapy market within hospital settings.
Technological Advances: Hospitals frequently maintain cutting-edge infrastructure and technological capabilities essential for the successful integration of image-guided radiation therapy (IGRT), thus assuring the ready availability of requisite resources. This pivotal attribute distinctly contributes to the advancement and fortification of the image-guided radiation therapy market.


“Asia Pacific to register significant growth rate in the market during the forecast period.”
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for image-guided radiation therapy. There are several drivers that contributed to this growth:
The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of image-guided radiation therapy (IGRT) substantiates its pivotal role in enhancing the market landscape.

The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like image-guided radiation therapy (IGRT), confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region’s desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of IGRT.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Prominent players in this market are Siemens Healthineers AG (Germany), Elekta (Sweden), Accuray Incorporated (US), GE Healthcare Company (US), and Hitachi (Japan), among others.

Research Coverage

• The report studies the image-guided radiation therapy market based on products, procedures, applications, end users, and regions.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global image-guided radiation therapy market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the image-guided radiation therapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:

• Analysis of key drivers (increasing prevalence of cancer patient population, Increasing  government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of image-guided radiation therapy treatment, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the image-guided radiation therapy market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the image-guided radiation therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the image-guided radiation therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the image-guided radiation therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.

Table of Contents

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 REGIONS COVERED 26
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 27
1.4 RESEARCH LIMITATIONS 27
1.5 MARKET STAKEHOLDERS 28
1.6 SUMMARY OF CHANGES 28
1.6.1 RECESSION IMPACT 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY RESEARCH 33
2.1.2.1 Primary sources 34
2.1.2.2 Key industry insights 35
2.1.2.3 Breakdown of primaries 35
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 36
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 37
2.2.1 BOTTOM-UP APPROACH 37
2.2.1.1 Approach 1: Company revenue estimation approach 38
FIGURE 5 IMAGE-GUIDED RADIATION THERAPY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 38
2.2.1.2 Approach 2: Customer-based market estimation 39
FIGURE 6 IMAGE-GUIDED RADIATION THERAPY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 39
2.2.1.3 Approach 3: Top-down approach 39
2.2.1.4 Approach 4: Primary interviews 40
FIGURE 7 TOP-DOWN APPROACH 40
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 42
FIGURE 8 DATA TRIANGULATION METHODOLOGY 42
2.4 ASSUMPTIONS AND RISK ASSESSMENT 43
TABLE 1 IMAGE-GUIDED RADIATION THERAPY MARKET: ASSUMPTIONS 43
TABLE 2 IMAGE-GUIDED RADIATION THERAPY MARKET: LIMITATIONS 43
2.5 RECESSION IMPACT ANALYSIS 44
3 EXECUTIVE SUMMARY 45
FIGURE 9 IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 45
FIGURE 10 IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46
FIGURE 11 IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 12 IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 48
FIGURE 13 IMAGE-GUIDED RADIATION THERAPY MARKET: GEOGRAPHICAL SNAPSHOT 49
4 PREMIUM INSIGHTS 50
4.1 IMAGE-GUIDED RADIATION THERAPY MARKET OVERVIEW 50
FIGURE 14 INCREASING CANCER PATIENT POPULATION AND GROWING NONINVASIVE CANCER TREATMENT TO DRIVE MARKET 50
4.2 REGIONAL MIX: IMAGE-GUIDED RADIATION THERAPY MARKET (2021–2028) 51
FIGURE 15 NORTH AMERICA TO DOMINATE MARKET THROUGHOUT FORECAST PERIOD 51
4.3 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY AND END USER, 2022 (USD MILLION) 52
FIGURE 16 HOSPITALS DOMINATED IMAGE-GUIDED RADIATION THERAPY MARKET IN 2022 52
4.4 IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY 52
FIGURE 17 MEXICO TO GROW AT HIGHEST RATE IN GLOBAL MARKET 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 18 IMAGE-GUIDED RADIATION THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Rising adoption of radiotherapy for noninvasive cancer treatment 54
5.2.1.2 Rising cancer patient population 54
FIGURE 19 OVERVIEW OF CANCER PATIENT POPULATION: MALE VS. FEMALE 55
TABLE 3 RISE IN CANCER CASES, 2020 VS. 2025 VS. 2030 55
5.2.1.3 Initiatives and support for cancer management 56
5.2.2 RESTRAINTS 56
5.2.2.1 Complexity of imaging technology 56
5.2.2.2 Affordability and accessibility of treatment 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Expansion of key players in emerging economies 57
5.2.3.2 Rising healthcare expenditure across emerging economies 58
FIGURE 20 GOVERNMENT HEALTH EXPENDITURE AS % OF GENERAL GOVERNMENT EXPENDITURE (GGE) 58
5.2.4 CHALLENGES 59
5.2.4.1 Availability of alternatives to IGRT 59
5.2.4.2 Dearth of skilled personnel 59
5.3 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 4 IMAGE-GUIDED RADIATION THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.3.1 THREAT OF NEW ENTRANTS 60
5.3.2 THREAT OF SUBSTITUTES 60
5.3.3 BARGAINING POWER OF SUPPLIERS 60
5.3.4 BARGAINING POWER OF BUYERS 60
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.4 ECOSYSTEM MAPPING 61
FIGURE 21 IMAGE-GUIDED RADIATION THERAPY MARKET: ECOSYSTEM MAP 61
5.5 VALUE CHAIN ANALYSIS 62
5.5.1 RESEARCH & DEVELOPMENT 62
5.5.2 PROCUREMENT AND PRODUCT DEVELOPMENT 62
5.5.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES 62
FIGURE 22 IMAGE-GUIDED RADIATION THERAPY MARKET: VALUE CHAIN ANALYSIS 62
5.6 SUPPLY CHAIN ANALYSIS 63
5.6.1 PROMINENT COMPANIES 63
5.6.2 SMALL & MEDIUM-SIZED COMPANIES 63
5.6.3 END USERS 63
FIGURE 23 IMAGE-GUIDED RADIATION THERAPY MARKET: SUPPLY CHAIN ANALYSIS 63
5.7 REGULATORY ANALYSIS 64
5.7.1 US 64
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.7.2 EUROPE 65
5.7.3 JAPAN 65
TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 66
5.8 REIMBURSEMENT SCENARIO 66
TABLE 7 CPT CODES FOR MAJOR AUTOMATED RADIATION THERAPY TREATMENT MODALITIES 66
TABLE 8 HEALTHCARE COMMON PROCEDURE CODING SYSTEM (HCPCS) CODES FOR IGRT 67
TABLE 9 REIMBURSEMENT FOR IMAGE-GUIDED RADIATION THERAPY PROCEDURES PER COURSE, 2021 VS. 2022 67
TABLE 10 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 68
5.9 PRICING ANALYSIS 68
TABLE 11 PRICING ANALYSIS OF AUTOMATED RADIATION SYSTEMS (USD) 68
5.10 PATENT ANALYSIS 69
TABLE 12 IMPORT DATA FOR IMAGE-GUIDED RADIATION THERAPY (HS CODE 9022), BY COUNTRY, 2018–2022 (USD THOUSAND) 69
TABLE 13 EXPORT DATA FOR IMAGE-GUIDED RADIATION THERAPY (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND) 70
5.11 CASE STUDY 70
TABLE 14 CASE STUDY: ENABLING MR-GUIDED SBRT TREATMENTS FOR PROSTATE CANCER 70
5.12 KEY CONFERENCES AND EVENTS, 2023–2024 71
TABLE 15 IMAGE-GUIDED RADIATION THERAPY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024 71
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 72
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 72
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR IMAGE-GUIDED RADIATION THERAPY MARKET 72
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%) 73
5.15 IMAGE-GUIDED RADIATION THERAPY MARKET: RECESSION IMPACT 73
6 IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE 74
6.1 INTRODUCTION 75
TABLE 17 IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 75
6.2 LINACS 75
6.2.1 LINACS TO HOLD LARGEST MARKET SHARE TILL 2028 75
TABLE 18 LINACS MARKET, BY REGION, 2020–2028 (USD MILLION) 76
TABLE 19 LINACS MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 76
TABLE 20 LINACS MARKET, BY APPLICATION, 2020–2028(USD MILLION) 77
TABLE 21 LINACS MARKET, BY END USER, 2020–2028 (USD MILLION) 77
6.3 CT SCANNING 77
6.3.1 GROWING NUMBER OF IMAGE-GUIDED AND MINIMALLY INVASIVE MEDICAL PROCEDURES TO BOOST MARKET 77
TABLE 22 CT SCANNING MARKET, BY REGION, 2020–2028 (USD MILLION) 78
TABLE 23 CT SCANNING MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 78
TABLE 24 CT SCANNING MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 79
TABLE 25 CT SCANNING MARKET, BY END USER, 2020–2028 (USD MILLION) 79
6.4 PORTAL IMAGING 79
6.4.1 TRANSITION FROM MANUAL TO ROBOTIC TREATMENT TO SUPPORT MARKET GROWTH 79
TABLE 26 PORTAL IMAGING MARKET, BY REGION, 2020–2028 (USD MILLION) 80
TABLE 27 PORTAL IMAGING MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 80
TABLE 28 PORTAL IMAGING MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 81
TABLE 29 PORTAL IMAGING MARKET, BY END USER, 2020–2028 (USD MILLION) 81
6.5 4D GATING/4D RADIATION THERAPY 82
6.5.1 RISING NUMBER OF CANCER TREATMENTS TO DRIVE MARKET 82
TABLE 30 4D GATING/4D RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 82
TABLE 31 4D GATING/4D RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 82
TABLE 32 4D GATING/4D RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 83
TABLE 33 4D GATING/4D RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 83
6.6 PET/MRI-GUIDED RADIATION THERAPY 83
6.6.1 LARGE PATIENT POPULATION FOR CANCER TO DRIVE MARKET 83
TABLE 34 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 84
TABLE 35 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 84
TABLE 36 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 85
TABLE 37 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 85
7 IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE 86
7.1 INTRODUCTION 87
TABLE 38 IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 87
7.2 IMRT 87
7.2.1 IMRT TO HOLD LARGEST MARKET SHARE OVER FORECAST PERIOD 87
TABLE 39 IMRT MARKET, BY REGION, 2020–2028 (USD MILLION) 88
7.3 3D CONFORMAL RADIATION THERAPY 88
7.3.1 ADVANTAGES AND INCREASED ADOPTION OF RADIATION THERAPY TO BOOST ADOPTION 88
TABLE 40 3D CONFORMAL RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 89
7.4 STEREOTACTIC THERAPY 89
7.4.1 HIGH PRECISION AND EASE OF USE FOR SURGEONS TO DRIVE ADOPTION 89
TABLE 41 STEREOTACTIC THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 90
7.5 PARTICLE THERAPY 90
7.5.1 GOVERNMENT SUPPORT TO BOOST NUMBER OF PARTICLE THERAPY CENTERS 90
TABLE 42 PARTICLE THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 90
7.6 PROTON BEAM THERAPY 91
7.6.1 RISING ESTABLISHMENT OF PROTON THERAPY CANCER CENTERS TO DRIVE MARKET 91
TABLE 43 PROTON BEAM THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 91
8 IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION 92
8.1 INTRODUCTION 93
TABLE 44 IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 93
8.2 BREAST CANCER 93
8.2.1 BREAST CANCER TO HOLD LARGEST SHARE OF APPLICATIONS MARKET 93
TABLE 45 IMAGE-GUIDED RADIATION THERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2028 (USD MILLION) 94
8.3 LUNG CANCER 94
8.3.1 RISING NUMBER OF CLINICAL TRIALS TO SUPPORT GROWTH 94
TABLE 46 IMAGE-GUIDED RADIATION THERAPY MARKET FOR LUNG CANCER, BY REGION, 2020–2028 (USD MILLION) 95
8.4 PROSTATE CANCER 95
8.4.1 PREFERENCE FOR NONINVASIVE TREATMENT TO BOOST GROWTH 95
TABLE 47 IMAGE-GUIDED RADIATION THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2028 (USD MILLION) 95
8.5 HEAD & NECK CANCER 96
8.5.1 RISING AWARENESS OF BENEFITS OF NONINVASIVE TREATMENTS TO SUPPORT GROWTH 96
TABLE 48 IMAGE-GUIDED RADIATION THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2020–2028 (USD MILLION) 96
8.6 GYNECOLOGICAL CANCER APPLICATIONS 97
8.6.1 GROWING AWARENESS AND NEED FOR EARLY, EFFECTIVE TREATMENT TO SUPPORT ADOPTION 97
TABLE 49 IMAGE-GUIDED RADIATION THERAPY MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2020–2028(USD MILLION) 97
8.7 GASTROINTESTINAL CANCER 97
8.7.1 RISING GI CANCER INCIDENCE TO BOOST MARKET GROWTH 97
TABLE 50 IMAGE-GUIDED RADIATION THERAPY MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2020–2028 (USD MILLION) 98
8.8 OTHER APPLICATIONS 98
TABLE 51 IMAGE-GUIDED RADIATION THERAPY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 99
9 IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER 100
9.1 INTRODUCTION 101
TABLE 52 IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 101
9.2 HOSPITALS 101
9.2.1 LARGE NUMBER OF SURGICAL AND DIAGNOSTIC PROCEDURES TO PROPEL MARKET 101
TABLE 53 IMAGE-GUIDED RADIATION THERAPY MARKET FOR HOSPITALS, BY REGION, 2020–2028 (USD MILLION) 102
9.3 INDEPENDENT RADIOTHERAPY CENTERS 102
9.3.1 LIMITED SURGICAL CAPABILITIES OF AVAILABLE PRODUCTS TO RESTRAIN ADOPTION 102
TABLE 54 IMAGE-GUIDED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2020–2028 (USD MILLION) 103
10 IMAGE-GUIDED RADIATION THERAPY MARKET, BY REGION 104
10.1 INTRODUCTION 105
TABLE 55 IMAGE-GUIDED RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 105
10.2 NORTH AMERICA 105
10.2.1 NORTH AMERICA: RECESSION IMPACT 105
FIGURE 26 NORTH AMERICA: MARKET SNAPSHOT 106
TABLE 56 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 107
TABLE 57 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 107
TABLE 58 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 108
TABLE 59 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 108
TABLE 60 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 109
10.2.2 US 109
10.2.2.1 US to dominate North American market 109
TABLE 61 US: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 109
10.2.3 CANADA 110
10.2.3.1 Rising cancer prevalence and growing awareness to drive market 110
TABLE 62 CANADA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 110
10.3 EUROPE 111
10.3.1 EUROPE: RECESSION IMPACT 111
TABLE 63 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 111
TABLE 64 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 112
TABLE 65 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 112
TABLE 66 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 113
TABLE 67 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 113
10.3.2 GERMANY 114
10.3.2.1 Germany to dominate market in Europe 114
TABLE 68 GERMANY: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 114
10.3.3 UK 115
10.3.3.1 High burden of cancer and large volume of radiation therapy procedures to ensure demand 115
TABLE 69 UK: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 115
10.3.4 FRANCE 115
10.3.4.1 Growth of French healthcare sector to support market growth 115
TABLE 70 FRANCE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 116
10.3.5 ITALY 116
10.3.5.1 Increasing geriatric population to aid growth 116
TABLE 71 ITALY: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 116
10.3.6 SPAIN 117
10.3.6.1 Technological developments in healthcare sector to propel market 117
TABLE 72 SPAIN: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 117
10.3.7 REST OF EUROPE 117
TABLE 73 REST OF EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 118
10.4 ASIA PACIFIC 118
10.4.1 ASIA PACIFIC: RECESSION IMPACT 118
FIGURE 27 ASIA PACIFIC: MARKET SNAPSHOT 119
TABLE 74 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 120
TABLE 75 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 120
TABLE 76 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 121
TABLE 77 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 121
TABLE 78 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 122
10.4.2 JAPAN 122
10.4.2.1 Japan to hold largest share of APAC market 122
TABLE 79 JAPAN: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 123
10.4.3 CHINA 123
10.4.3.1 Growing prevalence of cancer and developing healthcare infrastructure to aid growth 123
TABLE 80 CHINA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 124
10.4.4 INDIA 124
10.4.4.1 Increasing target patient population and rising availability of advanced surgical treatments to drive market 124
TABLE 81 INDIA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 125
10.4.5 AUSTRALIA 125
10.4.5.1 Developing healthcare sector and increasing availability of advanced surgical treatments to favor market 125
TABLE 82 AUSTRALIA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 125
10.4.6 SOUTH KOREA 126
10.4.6.1 Growing target patient population to drive market 126
TABLE 83 SOUTH KOREA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 126
10.4.7 REST OF ASIA PACIFIC 127
TABLE 84 REST OF ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 127
10.5 LATIN AMERICA 127
10.5.1 LATIN AMERICA: RECESSION IMPACT 127
TABLE 85 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 128
TABLE 86 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 128
TABLE 87 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 129
TABLE 88 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 129
TABLE 89 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 130
10.5.2 BRAZIL 130
10.5.2.1 Developing healthcare sector and increasing availability of advanced surgical treatments to boost market growth 130
TABLE 90 BRAZIL: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 130
10.5.3 MEXICO 131
10.5.3.1 Favorable government initiatives to drive market 131
TABLE 91 MEXICO: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 131
10.5.4 REST OF LATIN AMERICA 132
TABLE 92 REST OF LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 132
10.6 MIDDLE EAST & AFRICA 132
10.6.1 INCREASING FOCUS OF MARKET PLAYERS ON MIDDLE EASTERN COUNTRIES TO PROPEL MARKET 132
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 133
TABLE 93 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 133
TABLE 94 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 133
TABLE 95 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 134
TABLE 96 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 134
11 COMPETITIVE LANDSCAPE 135
11.1 OVERVIEW 135
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 135
TABLE 97 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMAGE-GUIDED RADIATION THERAPY MARKET 136
11.3 REVENUE SHARE ANALYSIS 137
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN IMAGE-GUIDED RADIATION THERAPY MARKET, 2018–2022 (USD BILLION) 137
11.4 MARKET RANKING ANALYSIS 138
FIGURE 29 IMAGE-GUIDED RADIATION THERAPY MARKET (2022) 138
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 139
11.5.1 STARS 139
11.5.2 EMERGING LEADERS 140
11.5.3 PERVASIVE PLAYERS 140
11.5.4 PARTICIPANTS 140
FIGURE 30 IMAGE-GUIDED RADIATION THERAPY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 140
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 141
11.6.1 PROGRESSIVE COMPANIES 141
11.6.2 STARTING BLOCKS 141
11.6.3 RESPONSIVE COMPANIES 141
11.6.4 DYNAMIC COMPANIES 141
FIGURE 31 IMAGE-GUIDED RADIATION THERAPY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/ SMES, 2022 142
11.7 COMPANY FOOTPRINT ANALYSIS 143
TABLE 98 TECHNIQUE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN IMAGE-GUIDED RADIATION THERAPY MARKET 143
TABLE 99 FOOTPRINT ANALYSIS OF COMPANIES, BY TECHNIQUE 144
TABLE 100 FOOTPRINT ANALYSIS OF COMPANIES, BY REGION 145
11.8 COMPETITIVE SCENARIOS AND TRENDS 146
TABLE 101 KEY PRODUCT LAUNCHES AND APPROVALS 146
TABLE 102 KEY DEALS 147
TABLE 103 OTHER KEY DEVELOPMENTS 147
12 COMPANY PROFILES 148
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 148
12.1.1 SIEMENS HEALTHINEERS AG 148
TABLE 104 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 148
FIGURE 32 SIEMENS AG: COMPANY SNAPSHOT (2022) 149
12.1.2 HITACHI 153
TABLE 105 HITACHI: COMPANY OVERVIEW 153
FIGURE 33 HITACHI: COMPANY SNAPSHOT (2022) 154
12.1.3 KONINKLIJKE PHILIPS 156
TABLE 106 KONINKLIJKE PHILIPS: COMPANY OVERVIEW 156
FIGURE 34 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT (2022) 157
12.1.4 ELEKTA 160
TABLE 107 ELEKTA: COMPANY OVERVIEW 160
FIGURE 35 ELEKTA: COMPANY SNAPSHOT (2022) 161
12.1.5 ACCURAY INCORPORATED 164
TABLE 108 ACCURAY INCORPORATED: COMPANY OVERVIEW 164
FIGURE 36 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2022) 165
12.1.6 CANON MEDICAL SYSTEMS CORPORATION 168
TABLE 109 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 168
FIGURE 37 CANON, INC.: COMPANY SNAPSHOT (2022) 169
12.1.7 C-RAD AB 171
TABLE 110 C-RAD: COMPANY OVERVIEW 171
FIGURE 38 C-RAD: COMPANY SNAPSHOT (2022) 172
12.1.8 VIEWRAY, INC. 174
TABLE 111 VIEWRAY, INC.: COMPANY OVERVIEW 174
FIGURE 39 VIEWRAY, INC.: COMPANY SNAPSHOT (2022) 175
12.1.9 IBA WORLDWIDE 177
TABLE 112 IBA: COMPANY OVERVIEW 177
FIGURE 40 IBA: COMPANY SNAPSHOT (2022) 178
12.1.10 VISION RT LTD. 180
TABLE 113 VISION RT LTD.: COMPANY OVERVIEW 180
12.1.11 PANACEA MEDICAL TECHNOLOGIES 182
TABLE 114 PANACEA MEDICAL TECHNOLOGIES: COMPANY OVERVIEW 182
12.1.12 MEVION MEDICAL SYSTEMS 184
TABLE 115 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 184
12.1.13 GE HEALTHCARE 186
TABLE 116 GE HEALTHCARE: COMPANY OVERVIEW 186
FIGURE 41 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 187
12.2 OTHER PLAYERS 190
12.2.1 REFLEXION 190
12.2.2 ASG SUPERCONDUCTORS 190
12.2.3 GALBINO TECHNOLOGY 191
12.2.4 IZI MEDICAL 191
12.2.5 XSTRAHL 192
12.2.6 AEP LINAC 192
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
13 APPENDIX 193
13.1 DISCUSSION GUIDE 193
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199
13.3 CUSTOMIZATION OPTIONS 201
13.4 RELATED REPORTS 201
13.5 AUTHOR DETAILS 202